• Western blot analysis of lysates from NIH/3T3 cells, using SEK1/MKK4 Antibody. The lane on the right is blocked with the synthesized peptide.
  • Western blot analysis of various cells using MEK-4 Polyclonal Antibody diluted at 1:1000

Anti-MAP2K4 antibody (46-95 aa) (STJ94084)

SKU:
STJ94084

Current Stock:
Host: Rabbit
Applications: WB/ELISA/IHC
Reactivity: Human/Mouse/Rat
Note: STRICTLY FOR FURTHER SCIENTIFIC RESEARCH USE ONLY (RUO). MUST NOT TO BE USED IN DIAGNOSTIC OR THERAPEUTIC APPLICATIONS.
Short Description: Rabbit polyclonal antibody anti-Dual specificity mitogen-activated protein kinase kinase 4 (46-95 aa) is suitable for use in Western Blot, ELISA and Immunohistochemistry research applications.
Clonality: Polyclonal
Conjugation: Unconjugated
Isotype: IgG
Formulation: Liquid in PBS containing 50% Glycerol, 0.5% BSA and 0.02% Sodium Azide.
Purification: The antibody was affinity-purified from rabbit antiserum by affinity-chromatography using epitope-specific immunogen.
Concentration: 1 mg/mL
Dilution Range: WB 1:500-2000
IHC-P 1:50-300
ELISA 2000-20000
Storage Instruction: Store at-20°C for up to 1 year from the date of receipt, and avoid repeat freeze-thaw cycles.
Gene Symbol: MAP2K4
Gene ID: 6416
Uniprot ID: MP2K4_HUMAN
Immunogen Region: 46-95 aa
Specificity: MEK-4 Polyclonal Antibody detects endogenous levels of MEK-4 protein.
Immunogen: The antiserum was produced against synthesized peptide derived from the human SEK1/MKK4 at the amino acid range 46-95
Post Translational Modifications Activated by phosphorylation on Ser-257 and Thr-261 by MAP kinase kinase kinases (MAP3Ks).
Function Dual specificity protein kinase which acts as an essential component of the MAP kinase signal transduction pathway. Essential component of the stress-activated protein kinase/c-Jun N-terminal kinase (SAP/JNK) signaling pathway. With MAP2K7/MKK7, is the one of the only known kinase to directly activate the stress-activated protein kinase/c-Jun N-terminal kinases MAPK8/JNK1, MAPK9/JNK2 and MAPK10/JNK3. MAP2K4/MKK4 and MAP2K7/MKK7 both activate the JNKs by phosphorylation, but they differ in their preference for the phosphorylation site in the Thr-Pro-Tyr motif. MAP2K4 shows preference for phosphorylation of the Tyr residue and MAP2K7/MKK7 for the Thr residue. The phosphorylation of the Thr residue by MAP2K7/MKK7 seems to be the prerequisite for JNK activation at least in response to pro-inflammatory cytokines, while other stimuli activate both MAP2K4/MKK4 and MAP2K7/MKK7 which synergistically phosphorylate JNKs. MAP2K4 is required for maintaining peripheral lymphoid homeostasis. The MKK/JNK signaling pathway is also involved in mitochondrial death signaling pathway, including the release cytochrome c, leading to apoptosis. Whereas MAP2K7/MKK7 exclusively activates JNKs, MAP2K4/MKK4 additionally activates the p38 MAPKs MAPK11, MAPK12, MAPK13 and MAPK14.
Protein Name Dual Specificity Mitogen-Activated Protein Kinase Kinase 4
Map Kinase Kinase 4
Mapkk 4
Jnk-Activating Kinase 1
Mapk/Erk Kinase 4
Mek 4
Sapk/Erk Kinase 1
Sek1
Stress-Activated Protein Kinase Kinase 1
Sapk Kinase 1
Sapkk-1
Sapkk1
C-Jun N-Terminal Kinase Kinase 1
Jnkk
Database Links Reactome: R-HSA-2559580
Reactome: R-HSA-2871796
Reactome: R-HSA-450321
Reactome: R-HSA-5210891
Reactome: R-HSA-5684264
Cellular Localisation Cytoplasm
Nucleus
Alternative Antibody Names Anti-Dual Specificity Mitogen-Activated Protein Kinase Kinase 4 antibody
Anti-Map Kinase Kinase 4 antibody
Anti-Mapkk 4 antibody
Anti-Jnk-Activating Kinase 1 antibody
Anti-Mapk/Erk Kinase 4 antibody
Anti-Mek 4 antibody
Anti-Sapk/Erk Kinase 1 antibody
Anti-Sek1 antibody
Anti-Stress-Activated Protein Kinase Kinase 1 antibody
Anti-Sapk Kinase 1 antibody
Anti-Sapkk-1 antibody
Anti-Sapkk1 antibody
Anti-C-Jun N-Terminal Kinase Kinase 1 antibody
Anti-Jnkk antibody
Anti-MAP2K4 antibody
Anti-JNKK1 antibody
Anti-MEK4 antibody
Anti-MKK4 antibody
Anti-PRKMK4 antibody
Anti-SEK1 antibody
Anti-SERK1 antibody
Anti-SKK1 antibody

Information sourced from Uniprot.org

12 months for antibodies. 6 months for ELISA Kits. Please see website T&Cs for further guidance